217 related articles for article (PubMed ID: 30692685)
21. MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-κB activation.
Liu X; Yue C; Shi L; Liu G; Cao Q; Shan Q; Wang Y; Chen X; Li H; Wang J; Gao S; Niu M; Yu R
J Cell Mol Med; 2020 Jul; 24(13):7550-7562. PubMed ID: 32452133
[TBL] [Abstract][Full Text] [Related]
22. Normal lymphocyte homeostasis and function in MALT1 protease-resistant HOIL-1 knock-in mice.
Skordos I; Driege Y; Haegman M; Kreike M; Staal J; Demeyer A; Beyaert R
FEBS J; 2023 Apr; 290(8):2032-2048. PubMed ID: 36479846
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological inhibition of MALT1 protease activity suppresses endothelial activation via enhancing MCPIP1 expression.
Li Y; Huang S; Huang X; Li X; Falcon A; Soutar A; Bornancin F; Jiang Z; Xin HB; Fu M
Cell Signal; 2018 Oct; 50():1-8. PubMed ID: 29913212
[TBL] [Abstract][Full Text] [Related]
24. Function and targeting of MALT1 paracaspase in cancer.
O'Neill TJ; Tofaute MJ; Krappmann D
Cancer Treat Rev; 2023 Jun; 117():102568. PubMed ID: 37126937
[TBL] [Abstract][Full Text] [Related]
25. Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
Liang X; Sun C; Li C; Yu H; Wei X; Liu X; Bao W; Shi Y; Sun X; Khamrakulov M; Yang C; Liu H
J Med Chem; 2021 Jul; 64(13):9217-9237. PubMed ID: 34181850
[TBL] [Abstract][Full Text] [Related]
26. MALT1 activation by TRAF6 needs neither BCL10 nor CARD11.
Bardet M; Seeholzer T; Unterreiner A; Woods S; Krappmann D; Bornancin F
Biochem Biophys Res Commun; 2018 Nov; 506(1):48-52. PubMed ID: 30336982
[TBL] [Abstract][Full Text] [Related]
27. Proteolytic Activity of the Paracaspase MALT1 Is Involved in Epithelial Restitution and Mucosal Healing.
Wittner L; Wagener L; Wiese JJ; Stolzer I; Krug SM; Naschberger E; Jackstadt R; Beyaert R; Atreya R; Kühl AA; Sturm G; Gonzalez-Acera M; Patankar JV; Becker C; Siegmund B; Trajanoski Z; Winner B; Neurath MF; Schumann M; Günther C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108564
[TBL] [Abstract][Full Text] [Related]
28. Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity.
Unterreiner A; Touil R; Anastasi D; Dubois N; Niwa S; Calzascia T; Bornancin F
J Vis Exp; 2019 Jan; (143):. PubMed ID: 30663686
[TBL] [Abstract][Full Text] [Related]
29. Identification of Tensin-3 as a MALT1 substrate that controls B cell adhesion and lymphoma dissemination.
Juilland M; Alouche N; Ubezzi I; Gonzalez M; Rashid HO; Scarpellino L; Erdmann T; Grau M; Lenz G; Luther SA; Thome M
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2301155120. PubMed ID: 38109544
[TBL] [Abstract][Full Text] [Related]
30. Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation.
Rozmus J; McDonald R; Fung SY; Del Bel KL; Roden J; Senger C; Schultz KR; McKinnon ML; Davis J; Turvey SE
Clin Immunol; 2016 Jul; 168():1-5. PubMed ID: 27109639
[TBL] [Abstract][Full Text] [Related]
31. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes.
Sun L; Deng L; Ea CK; Xia ZP; Chen ZJ
Mol Cell; 2004 May; 14(3):289-301. PubMed ID: 15125833
[TBL] [Abstract][Full Text] [Related]
32. MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.
McAuley JR; Bailey KM; Ekambaram P; Klei LR; Kang H; Hu D; Freeman TJ; Concel VJ; Hubel NE; Lee JL; Klei HB; Cheng J; Sekar P; Bridwell RE; Covic L; Lucas PC; McAllister-Lucas LM
Oncogene; 2019 Dec; 38(49):7384-7398. PubMed ID: 31420608
[TBL] [Abstract][Full Text] [Related]
33. Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.
Baens M; Stirparo R; Lampi Y; Verbeke D; Vandepoel R; Cools J; Marynen P; de Bock CE; Bornschein S
Eur J Immunol; 2018 Oct; 48(10):1728-1738. PubMed ID: 30025160
[TBL] [Abstract][Full Text] [Related]
34. MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.
Afonina IS; Elton L; Carpentier I; Beyaert R
FEBS J; 2015 Sep; 282(17):3286-97. PubMed ID: 25996250
[TBL] [Abstract][Full Text] [Related]
35. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1.
Staal J; Driege Y; Bekaert T; Demeyer A; Muyllaert D; Van Damme P; Gevaert K; Beyaert R
EMBO J; 2011 May; 30(9):1742-52. PubMed ID: 21448133
[TBL] [Abstract][Full Text] [Related]
36. Differential requirement for Malt1 in T and B cell antigen receptor signaling.
Ruland J; Duncan GS; Wakeham A; Mak TW
Immunity; 2003 Nov; 19(5):749-58. PubMed ID: 14614861
[TBL] [Abstract][Full Text] [Related]
37. Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies.
Juilland M; Thome M
Curr Opin Hematol; 2016 Jul; 23(4):402-9. PubMed ID: 27135977
[TBL] [Abstract][Full Text] [Related]
38. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.
Pelzer C; Cabalzar K; Wolf A; Gonzalez M; Lenz G; Thome M
Nat Immunol; 2013 Apr; 14(4):337-45. PubMed ID: 23416615
[TBL] [Abstract][Full Text] [Related]
39. A patent review of MALT1 inhibitors (2013-present).
Hamp I; O'Neill TJ; Plettenburg O; Krappmann D
Expert Opin Ther Pat; 2021 Dec; 31(12):1079-1096. PubMed ID: 34214002
[TBL] [Abstract][Full Text] [Related]
40. MALT1-Dependent Cleavage of HOIL1 Modulates Canonical NF-κB Signaling and Inflammatory Responsiveness.
Fung SY; Lu HY; Sharma M; Sharma AA; Saferali A; Jia A; Abraham L; Klein T; Gold MR; Noterangelo LD; Overall CM; Turvey SE
Front Immunol; 2021; 12():749794. PubMed ID: 34721419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
